National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research. This year’s class of 15 recipients—six first-time awards and nine renewals—hail from China, India, Bangladesh, Italy, Mexico, South..
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment   Aquestive Therapeutics, a pharmaceutical company specializing in advancing medicines to improve patients' lives, has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for their product Libervant™ (diazepam) Buccal Film. The NDA is specifically for the..
Plus Therapeutics, a clinical-stage pharmaceutical company, announced positive interim updates from its ReSPECT™ clinical trials at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. The ReSPECT-GBM Phase 1 trial showed safety and overall survival correlation with absorbed radiation dose in recurrent glioblastoma patients. The ReSPECT-LM Phase 1/Part A trial demonstrated..
Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US Microbot Medical Inc. (Nasdaq: MBOT) announced the successful completion of an extended pre-clinical study conducted by global key opinion leaders ("KOLs") and executives from the medical industry. The study took place over two days at a research lab in New York. A team of interventional radiologists util..
SK bioscience and Sanofi have announced positive results from the Phase II study of their 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202). The vaccine demonstrated positive safety and immunogenicity data in infants. The companies plan to start Phase III trials in the first half of 2024. The Phase II clinical trial evaluated the safety and immunogenicity of GBP41..
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders FSD Pharma Inc., a biopharmaceutical company dedicated to innovative solutions for neurodegenerative, inflammatory, and metabolic disorders, has released the outcomes of its annual general and special meeting of shareholders held on June 29, 2023. During the meeting, there were 148 shareholders present or rep..
